Am I Eligible for Weight Loss Injections?

Am I eligible for weight loss injections? This is one of the most common questions asked by people considering medicines such as Mounjaro (tirzepatide) or Wegovy (semaglutide) for chronic weight management. Eligibility depends on your BMI, any weight-related health conditions you have, and whether you are accessing treatment through the NHS or a private provider. This article explains the clinical criteria, how NHS and private pathways differ, what to expect at your first assessment, and the safety considerations that a prescriber will review before any medicine is started.

Who is eligible for weight loss injections on the NHS?

NHS eligibility is based on BMI, weight-related comorbidities, and referral to a specialist Tier 3 or Tier 4 weight management service, with criteria set by NICE and local Integrated Care Boards.

NHS eligibility for weight loss injections is determined by a combination of body mass index (BMI), the presence of weight-related health conditions, and whether you are being treated within a specialist weight management service. These medicines are licensed for use in adults. NICE technology appraisals set out the criteria that Integrated Care Boards (ICBs) use when making local commissioning decisions, so access can vary depending on where you live in England, Wales, Scotland or Northern Ireland.

Currently, NICE recommends semaglutide (Wegovy) and tirzepatide (Mounjaro) for chronic weight management in adults within specialist NHS weight management services, subject to specific BMI and comorbidity thresholds.^[1][2] Both medicines are MHRA-authorised in the UK for this purpose. Liraglutide (Saxenda) is also MHRA-authorised for weight management and may be available in some NHS settings.^[6][7]

NHS specialist weight management services are typically delivered through Tier 3 or Tier 4 programmes, which provide structured, multidisciplinary support.^[1][3] Your GP is the right starting point for a referral to one of these services.

It is important to understand that a NICE recommendation does not automatically mean a medicine is commissioned everywhere. Your local ICB decides whether and how to fund these treatments, and some areas have introduced their own criteria or waiting lists. If you are unsure whether you qualify locally, speak to your GP.

For those who do not meet NHS criteria or who face long waiting times, private weight management services offer an alternative route. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a medicine may be considered if it is clinically appropriate.

What BMI and health conditions do you need to qualify?

NHS access to Wegovy or Mounjaro generally requires a BMI of at least 35 kg/m2 with at least one comorbidity such as type 2 diabetes, hypertension, or cardiovascular disease; lower thresholds apply for certain ethnic groups.

The BMI and health condition thresholds required to qualify for weight loss injections differ between individual medicines and between NHS and private pathways. For NHS access to Wegovy (semaglutide), NICE guidance specifies a BMI of at least 35 kg/m2 alongside at least one weight-related comorbidity, or a BMI of 30 to 34.9 kg/m2 in certain high-risk groups, when used within a specialist service. For Mounjaro (tirzepatide), NICE criteria similarly require a BMI of at least 35 kg/m2 with at least one weight-related comorbidity, or a lower BMI threshold for people from South Asian, Chinese, Black African, African-Caribbean or other ethnic backgrounds, where health risks occur at lower BMI values. NHS and NICE guidance provides specific numeric adjustments for these groups; your GP or specialist can advise on the applicable threshold for your circumstances.

Weight-related comorbidities that may support eligibility include:

• Type 2 diabetes

• Hypertension (high blood pressure)

• Obstructive sleep apnoea

• Cardiovascular disease

• Non-alcoholic fatty liver disease

• Dyslipidaemia (abnormal blood lipid levels)

For private services, eligibility criteria are set by the prescribing clinician and must remain within the limits of the UK product licence (for example, a BMI of at least 30 kg/m2, or at least 27 kg/m2 with a weight-related comorbidity, as specified in the relevant SmPC).^[8][12] Responsible providers conduct a thorough clinical assessment before prescribing.

NHS eligibility thresholds are fixed by NICE guidance and local ICB commissioning decisions and are not flexible. In private practice, the prescribing clinician applies clinical judgement within the boundaries of the UK product licence and good clinical practice. BMI alone is not always a complete measure of health risk, and clinicians may also consider waist circumference and ethnicity-adjusted thresholds when assessing suitability. If you are unsure whether you qualify, discuss your situation with a healthcare professional.

How do NHS and private weight loss injection services differ?

NHS services are subject to local commissioning decisions and can involve lengthy waiting times, while private services offer faster access but are self-funded and must still meet MHRA-authorised prescribing standards.

NHS and private weight loss injection services differ primarily in their eligibility criteria, waiting times, cost structure, and the level of ongoing support provided. On the NHS, treatment is delivered through specialist weight management services (Tier 3 or Tier 4) and is subject to local ICB commissioning decisions, meaning access is not uniform across the UK. Waiting times for specialist referral can be lengthy in some areas, and the range of medicines available may be limited by local formulary decisions.

Private services can offer faster access to assessment and, where clinically appropriate, to MHRA-authorised medicines such as Mounjaro (tirzepatide) or Wegovy (semaglutide). However, the cost of private treatment is met by the patient rather than the NHS, and prices vary between providers. It is important not to confuse a private consultation fee with the cost of the medicine itself, as these are separate charges.

When choosing a private provider, look for services that:

• Employ GMC-registered prescribers (verifiable at gmc-uk.org)

• Are registered with the GPhC if they supply medicines in Great Britain (verifiable at pharmacyregulation.org), or with the PSNI if operating in Northern Ireland (verifiable at psni.org.uk)

• Conduct a thorough clinical assessment before any prescription is issued

• Provide ongoing monitoring and support throughout treatment

Be cautious of online sellers that do not require a prescription or that cannot demonstrate registration with the appropriate regulator. The NHS provides guidance on buying medicines safely online, and purchasing from unregistered sources carries significant safety risks.

Whether you access treatment through the NHS or privately, the clinical standards for safe prescribing should be the same. A reputable service will not prescribe a weight management medicine without first confirming that it is appropriate for your individual health circumstances, and will arrange follow-up to monitor your progress and manage any side effects.

What happens at your first appointment and assessment?

A clinician will review your medical history, measure your BMI, arrange relevant blood tests, and discuss treatment options, dosing, and device use before initiating treatment at a low starting dose.

At your first appointment for a weight loss injection, a clinician will carry out a structured assessment to determine whether treatment is appropriate and safe for you. This assessment typically begins with a review of your medical history, current medications, and any existing health conditions, followed by measurements including your weight, height, and BMI calculation.

The clinician will also ask about:

• Previous attempts at weight management, including dietary changes, physical activity, and any prior use of weight loss medicines

• Family history of conditions relevant to treatment safety

• Current symptoms that might indicate an underlying cause of weight gain, such as thyroid disorders

• Mental health and eating patterns, as these can influence treatment suitability and outcomes

Blood tests may be arranged to check kidney function, liver function, fasting glucose, HbA1c, and lipid levels, depending on your individual circumstances and the medicine being considered. Pregnancy testing may also be carried out where clinically indicated. For people with type 2 diabetes, HbA1c measurement is standard.

Following the assessment, the prescriber will discuss the available options, explain how the medicine works, and outline what you can expect in terms of both benefits and potential side effects. You will also receive guidance on how to use the specific device correctly, including instructions for the Mounjaro KwikPen or Wegovy FlexTouch pen as applicable, and how to store it. The manufacturer's Instructions for Use (IFU), available via the electronic Medicines Compendium (emc) at medicines.org.uk, provide authoritative step-by-step guidance for each device. Treatment is initiated at a low dose and increased gradually according to the product SmPC to improve tolerability.^[12]

Ongoing appointments are an important part of any weight management programme. Regular check-ins allow the clinical team to monitor your response to treatment, adjust the dose if needed, and provide the dietary and behavioural support that improves long-term outcomes.

Are there any reasons you might not be able to use them safely?

Key contraindications and cautions include hypersensitivity to the medicine, a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, and pregnancy or breastfeeding.

Several medical situations may mean that weight loss injections are not suitable for you, and a thorough clinical assessment is essential before starting any of these medicines. According to the UK Summary of Product Characteristics (SmPC) for medicines such as Mounjaro and Wegovy, the formal contraindication is a known hypersensitivity to the active substance or any of the excipients. However, clinicians will consider a broader range of factors when assessing individual safety.

Conditions and circumstances that require careful consideration include:

• A personal or family history of pancreatitis, as acute pancreatitis, including post-marketing reports of necrotising pancreatitis with fatal outcomes, has been reported with this class of medicine^[10]

• Severe gastrointestinal disease, including gastroparesis, as these medicines slow gastric emptying

• Diabetic retinopathy: people with pre-existing pre-proliferative or proliferative diabetic eye disease should be monitored carefully, as rapid improvement in blood glucose control may be associated with transient worsening

• Severe renal or hepatic impairment, which may affect how the medicine is processed

• Gallbladder disease: symptoms such as upper-right abdominal pain or jaundice should prompt medical review, as gallbladder-related events have been reported with this class of medicine per the UK SmPCs^[12][15]

• Pregnancy and breastfeeding: these medicines are not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception. The UK SmPC for tirzepatide (Mounjaro) advises using an additional non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, as the medicine may reduce the absorption of oral contraceptives^[9][12]

If you experience symptoms such as severe and persistent abdominal pain, signs of a serious allergic reaction, or any other unexpected effects, contact your GP or call NHS 111 for urgent advice. For a life-threatening emergency, call 999 or go to your nearest A&E. Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Semaglutide for managing overweight and obesity (TA875).
2. Semaglutide for managing overweight and obesity – Recommendations (TA875, Chapter 1).
3. Tirzepatide for managing overweight and obesity (TA1026).
4. Tirzepatide for managing overweight and obesity – Recommendations (TA1026, Chapter 1).
5. NICE recommended weight-loss drug to be made available in specialist NHS services.
6. Saxenda – European Public Assessment Report.
7. Liraglutide | Drugs | BNF – NICE.
8. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
9. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
10. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
11. GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation.
12. Tirzepatide | Drugs | BNF – NICE.
13. NG242 Diabetic retinopathy: management and monitoring – Evidence review C: effectiveness of intensive treatments to lower blood glucose levels.
14. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.
15. Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study.
16. Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.

Frequently Asked Questions